Humacyte Q2 2022 Earnings Report
Key Takeaways
Humacyte reported revenue of $1.3 million for the second quarter of 2022, compared to $0.7 million for the second quarter of 2021. Net income was $36.9 million for the second quarter of 2022, compared to a net loss of $17.2 million for the second quarter of 2021. The company's cash, cash equivalents and short-term investments totaled $189.0 million as of June 30, 2022.
HAVs successfully implanted in wounded Ukrainian citizens and reported to be functioning, saving limbs
Hosted key opinion leader (KOL) webinar on HAV in the treatment of vascular trauma, featuring Ernest E. Moore, M.D and Gregory A. Magee, M.D.
Strengthened Board of Directors with appointment of Diane Seimetz, Ph.D. and leadership team with appointment of Shamik Parikh, M.D. as Chief Medical Officer
Multiple scientific meeting presentations and publications highlighting clinical HAV data in vascular trauma and arteriovenous access and preclinical small-diameter HAV data in coronary artery bypass grafting (CABG)
Humacyte
Humacyte
Forward Guidance
Humacyte believes that its cash, cash equivalents and short-term investments are adequate to fund operations through 2024, past the Company’s current expected timeline for potential approval of the HAV in vascular trauma.